Clinical Trials Logo

Acute Kidney Injury clinical trials

View clinical trials related to Acute Kidney Injury.

Filter by:

NCT ID: NCT04387149 Recruiting - Clinical trials for Novel Biomarkers of Acute Kidney Injury Following Cardiac Surgery

Biomarkers of Acute Kidney Injury Following Cardiac Surgery

Start date: January 6, 2020
Phase:
Study type: Observational

Acute kidney injury occurs in up to 30% of patients undergoing cardiac surgery. Cardiac surgery associated-acute kidney injury (CSA-AKI) is characterized by a sudden and sustained decrease in renal function with insufficient elimination waste products. The problem is that postoperative diagnosis of CSA-AKI is delayed because it relies solely upon the slow and unreliable rise in serum creatinine (SCr) levels that may lead to delayed start in treatment and increased risk of adverse outcomes. We hypothesize that Matrix Metalloproteins (MMPs) -2, -9 and Neutrophil gelatinase-associated lipocalin (NGAL) are associated with and earlier detectors of CSA-AKI compared to levels of SCr.

NCT ID: NCT04381351 Recruiting - COVID-19 Clinical Trials

Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction

MiRCOVID
Start date: April 16, 2020
Phase:
Study type: Observational

In this study, critically ill patients with highly suspected or confirmed COVID-19 will be included. Main goal is the identification of noncoding RNAs in COVID-19 associated organ dysfunction with an emphasis on acute kidney injury.

NCT ID: NCT04376619 Withdrawn - Acute Kidney Injury Clinical Trials

Preventing Acute Kidney Injury

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

Acute kidney injury increases the risk for chronic kidney disease, length of stay, readmissions and mortality. Currently the only way to diagnose acute kidney injury is with a serum creatinine or drop in urine output. Biomarkers for acute kidney injury are well elevated before rise in creatinine. Hypothesis is that by implementing an electronic alert system with an algorithm followed by remote ischemic preconditioning will prevent acute kidney injury.

NCT ID: NCT04358874 Active, not recruiting - Acute Kidney Injury Clinical Trials

Maximizing Acute Kidney Injury End-point Intervention Post-Discharge (MAKE-IT) Study

MAKE-IT
Start date: October 14, 2020
Phase: N/A
Study type: Interventional

This purpose of this pilot and feasibility study is to determine whether attending an acute kidney injury (AKI) clinic after discharge from the hospital impacts prescription medicine use, blood pressure and recovery of kidney function as compared to usual care.

NCT ID: NCT04358016 Completed - Cirrhosis, Liver Clinical Trials

Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding

Start date: January 1, 2018
Phase: Phase 4
Study type: Interventional

The investigators studied the renal function index level in terlipressin treated cirrhotic patients with upper-gastrointestinal bleeding at different time point.

NCT ID: NCT04354467 Completed - Acute Kidney Injury Clinical Trials

Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU

Start date: January 28, 2019
Phase:
Study type: Observational

Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of cases. Through initial work at UAB/Children's of Alabama Hospital, NTMx exposure was found to be potentially modifiable and the associated AKI is an avoidable adverse safety event. Currently, only serum Creatinine monitoring is available to monitor for NTMx-associated AKI. The hypothesis of this NINJA NGAL study is that urine NGAL is highly sensitive to detect NTMx-associated AKI. UAB/Children's of Alabama is bringing urine NGAL measurement to the infants in the NICU to detect NTMX-associated AKI.

NCT ID: NCT04353583 Active, not recruiting - Acute Kidney Injury Clinical Trials

Acute Kidney Injury and Acute Kidney Disease in COVID-19

Start date: April 21, 2020
Phase:
Study type: Observational [Patient Registry]

Acute kidney injury (AKI) has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of AKI and renal recovery of inpatients diagnosed with COVID-19.

NCT ID: NCT04343417 Enrolling by invitation - Acute Kidney Injury Clinical Trials

Biorepository to Support Research in Kidney Diseases

Start date: July 28, 2020
Phase:
Study type: Observational [Patient Registry]

To support advances in the understanding of pathophysiology and therapies of kidney diseases by creating a BioBank of kidney tissue, DNA, plasma, and urine from patients with kidney diseases.

NCT ID: NCT04342975 Completed - AKI Clinical Trials

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

This study is a single-center, prospective, randomized, double-blinded, placebo-controlled phase II clinical trial to evaluate the efficacy of "NAD+ supplementation" with Basis™ (Nicotinamide Riboside and Pterostilbene) in preventing acute kidney injury (AKI) in patients undergoing complex aortic aneurysm repair and open aortic arch reconstruction.

NCT ID: NCT04341974 Completed - Surgery Clinical Trials

Perioperative Use of Serum Creatinine and Postoperative Acute Kidney Injury

CreaPeriop
Start date: January 1, 2019
Phase:
Study type: Observational

The perioperative approach adopted in a cohort of adult oncological patients undergoing major abdominal surgery will be described. In particular, the physician's attitude toward use of sCr for identification of patients at risk for PO-AKI will be described, as well as the patients who should be reassessed in the long term for progression toward CKD. The incidence and risk factors associated with PO-AKI and renal function deterioration within a year postoperatively will be also evaluated.